Danish Merck collaboration is ahead of schedule

The Denmark-based biotech company, Nordic Bioscience, has completed enrollment of patients for a major phase II study conducted on behalf of German pharma giant Merck ahead of schedule – which makes the company hope for more.

stopur tid

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles